Tenders Are Invited For Pharmaceutical Products - Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Sorafenib (L01ex02) As Part Of A So-Called Open House Model.

Pharmaceutical Products - Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Sorafenib (L01ex02) As Part Of A So-Called Open House Model.. The Aok Rhineland-Palatinate/Saarland - The Health Insurance Company Offers Discount Contracts With The Active Ingredient Sorafenib (L01ex02) To All Interested Pharmaceutical Companies Without A Selection Decision. The Contracts Are Concluded As Part Of An “Open House Model”. The Contracts Offered Are Not Exclusive; Contracts With All Market Participants (Pharmaceutical Companies) Are Desired By Aok Rheinland-Pfalz/Saarland - The Health Insurance Fund. In The Open House Model, Uniform Conditions Apply To All Participants. Contract Contents, Conditions And Access Procedures Are Uniform - Individual Negotiations Are Not Carried Out. The Contract Terms Are A Maximum Of 24 Months; The Earliest Contract Start Date Is October 1St, 2024. All Contracts End No Later Than 24 Months After The Earliest Day Of Contract Start, Regardless Of The Date Of Conclusion Of The Respective Contract. Joining Or Concluding A Contract Can Take Place On The First Of Every Month Within The 24-Month Period. There Is A Right Of Termination 6 Weeks To The End Of The Month In Accordance With The Provisions Of The Contract. Further Information On Termination Options Is Contained In The Contract Documents. The Aok Rhineland-Palatinate/Saarland - The Health Insurance Fund Reserves The Right To Replace The Non-Exclusive Open House Discount Contracts With Exclusive Discount Contracts During The Contract Term As Part Of Europe-Wide Tendering Procedures. When Advertised, Exclusive Discount Contracts Come Into Force, The Open House Contracts Will Be Terminated In Accordance With The Contractual Provisions, I.E. The Open House Contracts Will End Automatically. Interested Pharmaceutical Companies Can Request The Participation Documents And Contract Documents From The Contact Address Mentioned. Contracts For The Active Ingredient Sorafenib (L01ex02) Will Be Concluded For The First Time With Effect From October 1St, 2024. Interested Parties Who Would Like To Become Contractual Partners On This Date Must Submit The Contractual Documents To Aok Rheinland-Pfalz/Saarland - The Health Insurance Fund By August 31, 2024. It Depends On Access To Aok Rheinland-Pfalz/Saarland - The Health Insurance Fund. Note: The First Award In This Procedure Will Be Awarded No Earlier Than 10 Calendar Days After Publication Of This Eu Notice In The Official Journal. Later Contracts Are Possible During The 24-Month Maximum Term On The First Of Each Month. For Interested Parties Who Would Like To Become A Contractual Partner On These Subsequent Dates, Receipt Of The Contract Documents Including The Attachments Must Be Submitted No Later Than The End Of The Month Preceding The Month Before The Desired Contract Start (E.G. Receipt On April 30Th If The Contract Starts On June 1St). The Exact Deadlines For Receipt Will Be Announced With The Contract Documents. This Publication Does Not Involve The Award Of A Public Contract Within The Meaning Of The Procurement Coordination Guidelines